Navigation Links
Asmacure Ltee Issued Patent to Govern Composition-of-Matter for its Nicotinic Receptor Technology in the U.S.
Date:10/25/2011

QUEBEC CITY, Oct. 25, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that it has been issued U.S. patent No. 8,039,459 from the United States Patent & Trademark Office (USPTO) entitled "Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases."  The first patent of this series in the USPTO comprises compounds and pharmaceutical composition claims.

"The issuance of these patents in the U.S. and Japan are important developments for the strong global intellectual property estate for our lead compound, ASM-024," said Mr. Martin Driscoll, CEO of Asmacure. "This important expansion of the patent protection for ASM-024 is another milestone in the development of our proprietary new mechanism for the treatment of asthma and other respiratory inflammatory diseases."

The nicotinic receptor agonist compounds developed for the treatment of pulmonary inflammatory diseases were discovered at the Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Quebec, a research center affiliated with Universite Laval. Asmacure has an exclusive license from Universite Laval to develop and commercialize any product derived from this technology.

On July 15, 2011, the Japan Patent Office issued the corresponding Japanese patent No. 4783787.  The claims within the patent are directed to compounds as well as pharmaceutical compositions for treating or preventing pulmonary inflammatory diseases.

About Asmacure

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases. The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma. ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada. The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec. For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asmacure Ltee to Present at the 2011 BIO Business Forum During the Annual BIO International Convention
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
4. Urgent Call Is Issued for More Local Doctors and Nurses for Mondays Free Health Clinic
5. U.S. Patent for Leatt Neck Brace System Issued
6. China Medical Technologies Announces the First Inclusion of FISH Tests for Diagnosis of Certain Hematological Malignancies in the Clinical Guidelines Issued by the MOH
7. PRA Experts Pulmonary Function Textbook Reissued
8. Voluntary Worldwide Field Correction Issued for the S98/98XT, CS100/CS100i and CS300 Intra-Aortic Balloon Pumps
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Landmark Patents Issued for ViewRay Technology
11. Two New U.S. Patents Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):